Arbutus Biopharma Corporation (ABUS) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, ABUS carries an RQD Score of 18 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 2 of 20 (ROIC -35%; FCF yield -6.04%), which is the weakest reading and signals that the business is not currently generating cash returns on invested capital. The Whale 13F Flow pillar scores 5 of 20 (institutional accumulation and options positioning), indicating limited supportive institutional flow in the source data. Insider Conviction scores 3 of 20 (SEC Form 4 and Congressional PTR cluster flow), and Macro Regime Fit scores 3 of 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 5 of 20 (Altman Z 1.34; Piotroski F 3/9; Debt/Equity 0.5), reflecting financial-distress signals. For a prospective investor, the implication is that the upside case rests on events outside current cash generation, while valuation support from earnings or cash flow is absent in the source data. The rating's verdict is an analytical classification, not a recommendation.

Arbutus Biopharma Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The source data does not describe its products, customers, or revenue model beyond reported financial figures. Reported revenue was $14.1M for FY 2025, per the SEC financials. Market capitalization is $0.7B per the profile, shown as $656.0M in market data.

Per the SEC financials, the company reported losses in each period shown, with operating margin of -60% and net margin of -60% per market data, and gross margin of 0%. ROIC is -35% per market data. Per the Roarable RQD rating, the Altman Z-Score is 1.34, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash declined from $36.3M to $18.0M between FY 2024 and FY 2025 per the SEC financials.

Per the recent news and catalysts feed, the most prominent items are: a Seeking Alpha report referencing a $230M buyback and Moderna cash, framed as de-risking a potential HBV cure path; a MyChesCo report stating Arbutus retires 23% of shares in a $230 Million buyback; a TradingView weekly recap referencing a Moderna $178M payment and AB-101 Phase 1 results; and a Mugglehead and Stock Titan report that the FDA lifted a clinical hold on AB-101, Arbutus' experimental oral hepatitis B drug. A Benzinga report references the stock trading higher. Catalyst-tagged items are the buyback and Moderna-related items; market-wire items cover the clinical hold lift and the Phase 1 results. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, and sector correlations beyond the stated Health Care sector and Biotechnology industry, are not available in source data. Second-order bottlenecks cannot be identified from the provided sources. Investors should monitor the Moderna payment referenced in news items as a counterparty-revenue dependency, while recognizing the source data does not quantify its share of revenue.

• What is the company's revenue composition, and how much of FY 2025 revenue of $14.1M derives from the Moderna payment referenced in news items?
• What is the cash runway given cash of $18.0M against FCF of $-39.6M in FY 2025?
• Are the Altman Z-Score of 1.34 and Piotroski F-Score of 3/9 expected to change, and what debt obligations sit behind the Debt/Equity of 0.5?
• What is the status and timeline of the AB-101 program following the lifted clinical hold, and what are the Phase 1 results in detail?
• What is the effect of the $230M buyback on share count and cash, given cash reported at $18.0M for FY 2025?